, which occurs in individuals who harbour mutations in FOXP3.
Approaches to increase the number and function of T reg cells could clearly benefit patients with auto immune disorders. Some of these approaches are now in clinical trials. One such effort involves adoptive T reg cell therapy [5] [6] [7] and includes the potential to engineer antigen specificity into the transferred T reg cells; in another, low-dose interleukin (IL)-2 is administered to selectively expand T reg cell populations, a strategy that could be applied to many patients with autoimmune diseases [8] [9] [10] . In addition, strategies to reduce the function and/or number of T reg cells are being investigated to promote antitumour immunity.
In this Review, we focus on therapies that target T reg cells and are now being exploited to treat autoimmune diseases and cancer. We discuss the biology and function of T reg cells and then highlight the current therapeutic approaches being investigated to either empower them or limit their suppressive capacity and expansion.
Biology of T reg cells
Developmental heterogeneity T reg cells are marked by the transcriptional regulator FOXP3 and constitute approximately 5-10% of peripheral CD4 + T cells in humans and mice 11 . FOXP3 is a reliable marker for mouse T reg cells. Even though FOXP3 is an intracellular protein, genetic reporter mice have facilitated rigorous purification of viable T reg cells for molecular and cellular analysis. In humans, T reg cells are characterized by constitutive expression of the transcription factor FOXP3, high expression of the low-avidity IL-2 receptor (IL-2R) α chain (CD25) and low levels of the IL-7R α-chain (CD127) 12, 13 (Supplementary Box 1). However, FOXP3 is a less reliable marker for the identification of T reg cells in humans because some activated effector T cells (T eff cells) also express this molecule, albeit transiently and often at a somewhat low level 
Self-tolerance
The inability to respond to self-antigens.
CD4
+ T cells T cells that recognize peptides presented by major histocompatibility complex class II molecules and provide help to B cells to produce antibodies or to CD8 + cells to produce cytotoxic responses.
Effector T cells
(T eff cells). Short-lived activated cells that defend the body in an immune response.
T helper 1 cells
(T H 1 cells). Cells that produce interleukin 2, interferon-γ and tumour necrosis factor and are pro-inflammatory.
T helper 17 cells
(T H 17 cells). Cells that produce interleukin-17 and play an important role in maintaining mucosal barriers and contributing to pathogen clearance at mucosal surfaces; they also propagate autoimmune and inflammatory pathology.
Co-stimulatory molecule
A membrane-bound or secreted product that is required for co-stimulation. This second signal (in addition to T cell receptor engagement) from an antigen-presenting cell to a T cell allows the T cell to become activated and produce cytokines. CD28 (on T cells) is the best known example.
Antigen-presenting cells (APCs) . Cells that display antigen complexed with major histocompatibility complex molecules on their surfaces, which they present to T cells.
Dendritic cells (DCs) . Cells that are named for their surface projections (which resemble the dendrites of neurons). They continuously sample the environment for antigen, which they process and present to T cells.
CD8 + T cells
Cytotoxic T cells that recognize peptides presented by major histocompatibility complex class I molecules.
FOXP3 controls many functions of T reg cells. FOXP3 stabilizes the T reg cell lineage in part by reinforcing a gene expression programme that is required for the suppressive function of T reg cells 2, 17, 18 . T reg cell populations expand in response to IL-2, and this cytokine is required for T reg cell survival. FOXP3 represses IL-2 expression, which is produced by T eff cells during immune reactions, and, thus, T reg cells are dependent on paracrine IL-2.
T reg cells are classified into two major groups on the basis of their developmental origins. One population of T reg cells, designated thymus-derived T reg (tT reg ) cells, develops in the thymus. Another population of T reg cells develops when conventional peripheral CD4 + T cells become activated by antigen and encounter certain environmental signals that promote FOXP3 expression and suppressive function. When this occurs in vitro, these T reg cells are designated induced T reg (iT reg ) cells, and when this occurs in vivo, these cells are designated peripherally induced T reg (pT reg ) cells (Supplementary Box 2; Supplementary Fig. 1 ).
Unlike tT reg cells, which constitute a stable population of suppressor cells, pT reg cells have substantial plasticity and may convert into T eff cells, which are characterized by the production of interferon-γ (IFNγ) and IL-17. This feature allows for a cellular response that adapts to conditions within specific tissue sites. For example, pT reg cells are abundant in the gut mucosa, where they promote tolerance to a normal microbiota. However, during an infection, the inflammatory environment may convert pT reg cells into T helper 1 cells (T H 1 cells) or T helper 17 cells (T H 17 cells) to promote an immune response 19 .
A two-step model has been proposed whereby signalling from the T cell receptor (TCR), the co-stimulatory molecule CD28 and IL-2R promotes tT reg cell development 20 (FIG. 1) . The first step depends on the engagement of TCR and CD28, which together define archetypal immune stimulation, whereby TCRs with high affinity for self-antigens interact with self-peptide-major histocompatibility complex (MHC) class II complexes on antigen-presenting cells (APCs) to initiate fairly strong TCR signalling that activates nuclear factor-κB (NF-κB), nuclear factor of activated T cells (NFAT) and forkhead box protein O (FOXO) transcription factors in CD4 + CD8 -thymocytes [21] [22] [23] . NFAT and FOXO bind directly to the promoter, conserved non-coding region 2 (CNS2) and CNS3 of the FOXP3 gene to drive FOXP3 expression and T reg cell development 18, 24, 25 . These cells then differentiate into IL-2-responsive T reg cell progenitors (CD4 + CD25 + CD122 high GITR high FOXP3 -T cells). In the second step, IL-2R signalling promotes these FOXP3 -T reg cell progenitors to further develop into fully functional mature FOXP3 + T reg cells by activation of signal transducer and activator of transcription 5 (STAT5) 20, 21 . STAT5 has been proposed to initiate the demethylation of CNS2, which would help facilitate FOXP3 transcription.
In addition to these primary signalling events, other molecules promote tT reg cell maturation. Some of these include TNF receptor superfamily (TNFRSF) members, such as GITR (also known as TNFRSF18), OX40 (also known as TNFRSF4) and TNFR2 (also known as TNFRSF1B), which function as co-stimulatory molecules to sensitize T reg cell precursors to IL-2 stimulation 26 . Another important aspect of tT reg cell development is that the phosphoinositide 3-kinase (PI3K) pathway, which mediates signalling downstream of the TCR, is attenuated in T reg cells relative to T eff cells owing to the upregulation of PTEN in T reg cells; PTEN is the main negative regulator of the PI3K pathway 27 . Whereas transforming growth factor β (TGFβ) is essential for pT reg cell development, its role in tT reg cell development is less clear, as mice lacking TGFβ signalling did not have a numerical defect in tT reg cells 28 . Other studies, however, suggest that TGFβ, stimulated by thymic apoptosis, is an essential factor for Foxp3 transcription and tT reg cell generation in the thymus [29] [30] [31] .
Functions and phenotypic heterogeneity
Multiple mechanisms have been ascribed to mouse and human T reg cells that suppress autoreactive T cells. One prominent mechanism is the secretion of proteins, such as IL-10, IL-35 and TGFβ, which suppress pro-inflammatory responses. T reg cells also promote the conversion of dendritic cells (DCs) to a tolerogenic state through surface expression of cytotoxic T lymphocyte protein 4 (CTLA4) 32, 33 , which down-modulates the expression of the co-stimulatory molecules CD80 and CD86 on APCs and stimulates DCs to produce the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO). Lymphocyte activation gene 3 (LAG3), an immune checkpoint receptor, and neuropilin 1 (NRP1) have also been suggested to promote tolerogenic DCs 34, 35 . In turn, DCs, particularly those chronically exposed to antigen and rendered tolerogenic, may promote T reg cell expansion and function (see below).
The ectoenzymes CD39 and CD73 are highly expressed on the surface of some T reg cells and these two enzymes together convert extracellular ATP to adenosine 36, 37 , which inhibits the proliferation of T eff cells and suppresses the function of DCs 38 . In addition, the high level of CD25 on T reg cells sequesters IL-2 within the microenvironment and therefore hampers IL-2-dependent activation of CD8 + T cells and natural killer (NK) cells [39] [40] [41] . Lastly, intratumoural T reg cells also exhibit direct cytotoxicity towards NK cells and autoreactive CD8 + T cells, which mediate tumour cell clearance 42, 43 . Two main subsets of mature T reg cells have been defined on the basis of distinctive phenotypes and gene expression. These are resting or naive T reg (nT reg ) cells and activated or effector T reg (eT reg ) cells, including tissueresident T reg cells
. eT reg cells differ critically from nT reg cells in that the former often express increased levels of immunosuppressive molecules, particularly IL-10, and have increased surface expression of tissue-seeking chemokine receptors 44 . This property, in conjunction with downregulation of CC-chemokine receptor 7 (CCR7) and L-selectin (also known as CD62L; these two protein are markers of naive cells), promotes the migration of highly functional T reg cells into tissues 45 . TCR repertoire analysis has shown numerous major clonotype expansions in eT reg cells from deep tissue draining lymph nodes; these clonotypes are absent or reduced in activated
Natural killer (NK) cells
Cytotoxic lymphocytes critical to the innate immune system that provide rapid responses to viral infection and respond to tumour formation. They express an array of activating and inhibitory receptors and produce interferon-γ. Figure 1 | Steps in T reg cell development in vivo and in vitro. a | The development of regulatory T (T reg ) cells in the thymus occurs in steps and requires the expression of the T cell receptor (TCR) followed by the expression of the interleukin 2 receptor (IL-2R). When the TCR and self-antigens interact at a moderate level of avidity (just below the threshold for negative selection), the α-chain of IL-2R (CD25) is expressed and accumulates on the cell surface; IL-2 then plays a central role in T reg cell development independently of the TCR. The expression of forkhead box P3 (FOXP3) increases following the TCR-self-peptide-major histocompatibility complex (MHC) interaction. Transcription factors downstream of TCR engagement become activated and bind to the gene promoter and conserved non-coding region 2 (CNS2) of FOXP3. The expression of FOXP3 is maintained in IL-2-responsive T reg cells. Signalling through IL-2R preserves the hypomethylated status of CNS2 by recruiting TET. IL-2R signalling also activates signal transducer and activator of transcription 5 (STAT5) to further increase FOXP3 expression. b | T reg cells that are generated in vivo outside the thymus arise from naive CD4 + T cells in response to transforming growth factor-β (TGFβ) and IL-2 in peripheral tissues. The expression of FOXP3 in these cells derives mainly from TCR interactions with non-self-antigen-MHC and IL-2R signalling, which affect CNS1, with minor contributions from TGFβ signalling. c | FOXP3 expression in in vitro-induced T reg (iT reg ) cells is activation-dependent and short-lived. The addition of TGFβ or IL-2 to the media results in CNS1 hypomethylation, as DNA (cytosine-5)-methyltransferase 1 (DNMT1) is excluded from the nucleus. Both cytokines activate SMAD3 and STAT5, which increase FOXP3 expression. Mechanistic or mammalian target of rapamycin (mTOR) inhibitors may contribute to the activation of T reg cells in vitro. The CNS2 in iT reg cells is only partially hypomethylated, and therefore, FOXP3 expression is somewhat unstable. CTLA4, cytotoxic T lymphocyte protein 4; mAb, monoclonal antibody; mTORC1, mTOR complex 1; NF-kB, nuclear factor-kB; NFAT, nuclear factor of activated T cells; PI3K, phosphoinositide 3-kinase. memory T reg cells from superficial lymph nodes and in nT reg cell populations, further suggesting that eT reg cells actively control autoimmunity 46 . Thus, eT reg cells exhibit characteristics important for re-establishing tolerance in autoimmune-inflamed tissues. Correspondingly, T reg cell-based therapies that promote eT reg cells are likely to be more efficacious in tissues that are undergoing an immune or autoimmune attack 47 . In many ways, the heterogeneity of T reg cells mirrors that reported for T H cells, and one might simply view T reg cells as activated T cells that suppress rather than promote immunity. An important parallel between T reg cells and T H cells is that key transcriptional regulators that are expressed in T H cells are also expressed by T reg cells and are associated with the suppression of the corresponding T H cell subset. For example, T reg cells that suppress T H 1 cells express T-BET (also known as T-box transcription factor TBX21), the signature transcription factor of T H 1 cells 48 . Likewise, T reg cells that suppress T helper 2 cells (T H 2 cells), T H 17 cells and T follicular helper cells (T FH cells) express GATA3, STAT3, and BCL6, respectively, which are key transcriptional regulators associated with each of these T H subsets [49] [50] [51] . The precise mechanism of how T reg cell subsets affect a particular type of T H cell response is not well understood. However, it is likely that both T reg cells and T H cells respond to similar environmental cues, which promote T reg cells to migrate to and counteract inflammatory responses promoted by the corresponding T H cell subset, thus preventing undesired bystander suppression 52 .
TCR and IL-2R signalling
T reg cell homeostasis in the periphery depends critically on TCR and IL-2R signals. In mice with conditional TCR ablation in T reg cells, nT reg cell numbers were readily maintained, whereas eT reg cell numbers were substantially reduced 53 . Thus, maintenance of the eT reg cell population depends on recent TCR stimulation. In addition, when placed in competitive, IL-2-limited environments, T reg cells that have intrinsically impaired IL-2R signalling compete poorly with wild-type T reg cells, showing clearly that IL-2 is important for their maintenance in secondary lymphoid tissues 45 . Recently IL-2-activated T reg cells in vivo, defined as those T reg cells that contain activated STAT5, are nT reg cells, indicating that this T reg cell subset is especially dependent on IL-2 for maintenance 45, 54 . IL-2 also promotes eT reg cell survival, as terminally differentiated (KLRG1 + ) eT reg cell numbers are reduced in mice with intrinsic defects in IL-2R signalling 55 . IL-2 promotes T reg cell survival in part by upregulating the transcription of the anti-apoptotic molecules BCL2 and MCL1 (REF.
56
).
Administration of IL-2 to mice (alone or as an IL-2-anti-IL-2 antibody complex to increase its bioavailability) promotes the proliferation of T reg cells in the periphery. This indicates that IL-2 is a potent growth factor for T reg cells and raises the possibility that it can be used as a means to directly expand these suppressive cells in the context of autoimmune diseases. The conundrum had been that IL-2 is well known to be a growth factor for T eff cells as well. Thus, the use of IL-2 in autoimmune diseases was thought to be contraindicated because IL-2 might also expand pathogenic self-reactive T cells. However, studies of genetically modified mice in which IL-2R signalling was impaired, but not abrogated, showed that low IL-2R signalling readily promoted the development and homeo stasis of T reg cells while the IL-2-dependent activation of T eff cells remained impaired 57, 58 . The high level of expression of CD25 on mouse and human T reg cells, relative to other lymphoid cells, is one key reason why T reg cells exhibit high sensitivity to low levels of IL-2. This was used to conceptualize the first investigation of IL-2 in the context of autoimmune diseases 9,10 and will be discussed in more detail below, as these approaches are in clinical trials.
Key molecules that control T reg cells
The list of molecules, including transcription factors, kinases and phosphatases, that are recognized to be important for the function of T reg cells is growing. These molecules offer additional targets for therapeutic exploitation.
Mechanistic target of rapamycin (mTOR) integrates cell signalling pathways and metabolic inputs and enables specific cell responses. mTOR is a serine/threonineprotein kinase in the PI3K-related kinase family that forms the catalytic subunit of two distinct protein complexes, known as mTOR complex 1 (mTORC1) and mTORC2. mTORC2 phosphorylates and activates AKT, a key effector of PI3K signalling that promotes cell survival, proliferation and growth through the phosphorylation and inhibition of several key substrates, which include transcription factors and kinases 59 . In T eff cells, mTOR signalling is high and increases the inflammatory response; mTOR activity is low in T reg cells 60 . Indeed, deletion of mTOR in all conventional CD4 + T cells results in a phenotype reminiscent of T reg cells 61 . However, a certain level of mTORC1 activity is necessary for T reg cells to meet their metabolic demands, which occurs through cholesterol and lipid metabolism, specifically through the mevalonate pathway 62 . mTORC1 is essential to T reg cell function, and when mTORC1 is conditionally knocked out in T reg cells, mice develop a severe lymphoproliferative autoimmune condition 62 . In T eff cells, mTOR upregulates genes associated with the pentose phosphate pathway and the glucose transporter 
300
). These two molecules are hallmarks of T helper 17 cells, which are present in large numbers in the intestine. Similarly, visceral adipose tissue T reg cells express peroxisome proliferator-activated receptor-γ to regulate insulin sensitivity 301, 302 . Visceral adipose tissue T reg cells also express high levels of the IL-33 receptor (IL-33R; also known as IL1RL1), which is required for their accumulation in visceral adipose tissue 303 . Some strains of gut microorganisms can induce T reg cells in the intestine 304 . Deletion of skin-resident T reg cells in mice leads to atopic dermatitis 305 . The biology and characteristics of human tissue-resident T reg cells have been reviewed 306, 307 . GLUT1 (also known as SLC2A1), thereby facilitating glucose entry into the cells and subsequent glycolysis. By contrast, in T reg cells, in a manner similar to that observed in memory CD8 + cells, mTOR is required not for glycolysis but rather for lipogenesis to maintain the functional capacity of these cells 63, 64 . These findings illustrate how mTORC1 integrates signalling from the TCR, IL-2 and nutrient availability to modulate lipogenic pathways that are essential for T reg cell function. Thus, although complete deletion of mTORC1 results in T reg cell dysfunction and autoimmunity, unrestrained mTORC1 activity also disrupts T reg cell homeostasis.
PTEN is a lipid phosphatase that negatively regulates PI3K by dephosphorylating phosphatidylinositol (3,4,5)-triphosphate (PIP3), the dominant signalling molecule produced by the kinase activity of PI3K 65 . PIP3 is highly expressed in T reg cells and regulates their differentiation 66 . It has been shown that the NRP1-semaphorin 4A (SEMA4A) axis stabilizes T reg cell function by restraining PI3K and potentiating PTEN activity 67 . Conditional deletion of PTEN in T reg cells in mice resulted in a systemic lymphoproliferative autoimmunity that resembled systemic lupus erythematosus (SLE) with high titres of anti-nuclear antibodies and immune complex glomerulonephritis. Mechanistically, all these changes were attributed to increased mTORC2 and AKT activity 27 . Protein phosphatase 2A (PP2A), a serine/threonine phosphatase, is crucial for T reg cell function. In mice, the catalytic activity of PP2A in T reg cells is substantially higher than in conventional T cells, and conditional deletion of PP2A in T reg cells leads to severe multi-organ autoimmune pathology. FOXP3 promotes the generation of ceramide, which activates the catalytic subunit of PP2A, which in turn inactivates mTORC1 but not mTORC2 (REF.
68
Other molecules, such as NOTCH, other transcription factors and chromatin remodellers (Supplementary Box 3), are also key to T reg cell function. Understanding the molecular and/or biochemical events that govern T reg cell function is vital to the development of new T reg cellbased therapeutic approaches. Manipulation of kinase or phosphatase activity, preferably in a cell-specific manner, may offer, as discussed below, opportunities to modulate inflammatory and autoinflammatory responses.
T reg cells in key human diseases

Monogenic diseases
Several monogenic conditions illustrate the importance of functioning T reg cells to human immune homeostasis. The prototypical example is FOXP3 deficiency, which results in IPEX syndrome, a disease that appears within the first several years of life in males and requires bone marrow transplantation 4, 69 . Patients with CD25 deficiency present with both autoimmunity and immunodeficiency and a disease that is clinically similar to IPEX syndrome. CD25 deficiency does not affect the number of FOXP3 + cells in the circulation but impairs their suppressive function by decreasing IL-10 production and increasing IL-2 availability (loss of the 'IL-2 sink') 70, 71 . Deficiency of or mutations in STAT5B 72, 73 , CTLA4 (REF. 74 ) or LRBA 75 also result in autoimmune phenotypes.
Systemic lupus erythematosus
T reg cells have been logically implicated in the pathophysiology of systemic autoimmune diseases, although their numbers and function have been reported to be variable 76 . This variability most likely reflects the heterogeneity of the disease and the small size of the studied cohorts. The clinical heterogeneity is confounded by diversity in experimental protocols, markers to identify T reg cells and the conditions and performance of functional assays [76] [77] [78] [79] . The proportion of activated T reg cells is reduced during the early phases of the disease, whereas the CD45RA -
FOXP3
low non-T reg cell population is increased in patients with active SLE 80 . In addition, T cells from patients with SLE have low levels of phosphorylated STAT5 upon stimulation with IL-2, suggesting an inherent T reg cell defect 81 . A small study reported decreased numbers of T reg cells in the kidneys of patients with lupus nephritis and anti-neutrophil cytoplasmic antibody-associated vasculitis 82 ; this finding suggests that T reg cells are involved in the repair of tissue damage and that approaches to direct T reg cells to the kidney could be therapeutically useful.
Organ-specific autoimmune diseases
In type 1 diabetes (T1D), inflammatory cells infiltrate the pancreatic islets and destroy the insulin-producing cells. The number of T reg cells is reduced during the early phases of the disease 83 .This numerical deficiency is exacerbated by their reduced ability to increase the expression of FOXP3 in response to IL-2 (REF.
84
) and the resistance of T eff cells to suppression 85 . Psoriasis is an inflammatory skin disease in which the dermis and subcutaneous tissue are infiltrated with T H 1 cells, T H 17 cells and other subsets of T cells that produce pro-inflammatory cytokines including TNF, IL-6, IFNγ and IL-17 (REF. 86 ). In patients with psoriasis, T reg cells, particularly those that express CCR5 (REF.
87
) and are present in the skin 88 or the bone marrow 89 , display poor function. More importantly, the local skin inflammatory milieu promotes T reg cell plasticity and differentiation into IL-17-producing cells 90 . Myasthenia gravis is characterized by worsening muscle weakness -the pathology originates from autoreactive T cells, which provide help to B cells to produce anti-acetylcholine receptor (ACHR) antibodies, which block the ACHR. T reg cells from patients with myasthenia gravis display decreased expression of FOXP3 and compromised suppressive function 91, 92 , which could reflect reduced IL-2-STAT5 signalling 93 . Finally, the expression of CTLA4, which has been linked to myasthenia gravis in genome-wide studies 94 , is reduced on T reg cells from patients with this disease 95 . T reg cells residing in the intestine of patients with inflammatory bowel disease (IBD) exhibit a normal phenotype and are functional in assays in vitro 96 . The number of T reg cells in the lamina propria under any condition of intestinal inflammation is increased, whereas the number is decreased in the periphery 97, 98 . It should be noted that T reg cells that are present in the lamina propria of patients with IBD do not suppress T eff cells because the TGFβ signalling pathway is defective in the intestinal mucosa 99 . The regulation of the inflammatory response in the gut and the balance between T reg cells, T eff cells and innate lymphoid cells are complex 100 . Substantial insights have been gained from the study of the contribution of the microbiota 101 , as has added complexity. Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system, and myelin-specific autoreactive T eff cells initiate a chronic autoimmune response within the central nervous system 102 . Experiments in a mouse model of multiple sclerosis showed that T reg cells are generated from encephalitogenic T cells that infiltrate the central nervous system 103 , but these cells fail to control autoimmune inflammation 104 . In patients with multiple sclerosis, the number of T reg cells is variable 105 , but these cells have compromised regulatory function 106 .
Transplantation
In transplanted organs, where the active alloimmune responses take place, T reg cells that develop in response to antigen presented directly by the donor APCs or by self APCs expand and gradually infiltrate the transplanted organ. Yet, early after transplantation, T reg cells fail to suppress the alloimmune inflammatory response 107, 108 . Inhibition of mTOR can simultaneously suppress T eff cell function and improve the ability of T reg cells to control the inflammatory response. Donor alloantigen-specific T reg cells are more effective and have substantially less nonspecific immunosuppression than polyclonal T reg cells. Polyclonal T reg cells can suppress T eff cells of various specificities (dominant suppression), and they can suppress T eff cells generated in response to alloantigens other than that for which they were originally induced (bystander suppression) 109, 110 . Cancer T reg cell numbers are increased in the circulation and within tumour sites of various tumour types in humans and mice. Mechanisms that lead to intratumoural T reg cell accumulation include increased recruitment through the interaction of chemokine receptor-expressing activated T reg cells and the chemokines that are produced in the tumour microenvironment 111, 112 (CCL2-CCR4
(REF.
113
), CCL5-CCR5, hypoxia-mediated CCL8-CCR10
(REFS 114, 115 ) and CXCL12-CXCR4), local expansion of tT reg cells 111, 112, 116 and higher resistance of T reg cells than T eff cells to the reactive oxygen species in the tumour microenvironment, which results in a relative increase in T reg cell number 117, 118 . Another possibility is that pT reg cells that are generated de novo from conventional CD4 + cells in the tumour microenvironment [119] [120] [121] , but this has been challenged by TCR profiling studies, which did not show that the TCR repertoires in intratumoural T reg cells and conventional CD4 + T cells are largely overlapping in carcinogen-induced mouse 122 and human 123 tumours. The second challenge to this theory is that intratumoural T reg cells originate from tT reg cells, which recognize self-antigens specific to the organ of cancer origin 124, 125 . Finally, tumour-generated metabolites may favour intratumoural retention and survival of T reg cells over T eff cells. Specifically, the increased glycolytic activity of cancer cells may create a glucose-deprived, lactic acidenriched and fatty acid-enriched microenvironment, which favours T reg cell survival, as these cells utilize fatty acid oxidation and oxidative phosphorylation to generate energy, whereas T eff cells utilize aerobic glycolysis and anabolism for their bioenergetics needs 126, 127 . High levels of IDO 128 and adenosine 129 in the cancer microenvironment may be additional supportive mechanisms for intratumoural T reg cell generation and function.
The intratumoural accumulation of T reg cells has been associated with metastatic disease in several mouse tumour models 118, 130 and, more importantly, with advanced-stage disease and decreased survival in patients with cancer 131 . Furthermore, a reduced CD8 + T cell to T reg cell ratio in the tumour site is predictive of poor clinical outcome 132 . Collective experimental and clinical evidence supports the notion that intratumoural T reg cells facilitate tumour growth and progression by suppressing anti tumour immune responses, promoting tumour angio genesis 114, 115 and stimulating metastasis via receptor activator of NF-κB ligand (RANKL; also known as TNFSF11) signalling 133 . Some studies indicated a better prognosis for colo rectal cancers with FOXP3 + T cell infiltrates 134 . However, a recent study showed that certain colorectal cancers contain an abundance of FOXP3 low CD45RA
-non-T reg cells, which secrete pro-inflammatory cytokines, and that these patients have a better prognosis than those with a predominant FOXP3 high CD45RA
-T reg cell population 135 . This difference in FOXP3 expression could account for the conflicting data, as the distinction between FOXP3 low cells and FOXP3 high cells by immunohistochemistry could have been difficult. Tumour-resident T reg cells may suppress cytotoxic immune responses by contact-dependent (involving CTLA4, programmed cell death 1 ligand 1 (PD-L1), LAG3, NRP1, CD39 or CD73) or contactindependent (involving IL-10, TGFβ, granzyme, galectin 1, adenosine, prostaglandin E2 (PGE 2 ) or IDO) mechanisms or may acquire unique tumour-specific immunoregulatory mechanisms, as recently reported for specialized tissue-resident T reg cells that were epigenetically reprogrammed to express tissue-appropriate molecules 136 . In this way, tumours may behave as newly formed tissues with specialized immunoregulatory microenvironments. For example, a recent report indicates that the SEMA4A-NRP1 pathway is utilized by T reg cells to potentiate their function exclusively in tumours and not in other tissues 67 . Understanding the tumour-specific mechanisms that T reg cells utilize for their function will help design more effective and less toxic cancer immunotherapies.
Therapies: autoimmunity and transplants
As there is a homeostatic balance between the regulatory and effector arms of the immune response, any autoimmune or inflammatory disease marks the failure of the regulatory arm to efficiently control the effector arm 10 and thus implies T reg cell insufficiency. Importantly, this does not necessarily indicate a T reg cell numerical or functional deficiency but only defective overall performance. Current treatment of autoimmune or inflammatory diseases focuses on the reduction of the effector arm of the immune response with nonspecific immunosuppressant drugs. The discovery of T reg cells and the understanding of the balance between the effector and regulatory arms of the immune response have opened the path to approaches to expand the overall capacity of T reg cells to tilt the balance against the inflammatory process. Now, drugs and biologics are needed to improve T reg cell performance (FIG. 2) .
Polyclonal T reg cell therapies
In the absence of a specific means to activate and expand T reg cells in vivo, their therapeutic potential was first explored as cell therapy (TABLE 1) . This raised the important question of how to purify these cells efficiently without contamination by T eff cells. Indeed, the best marker to characterize T reg cells, FOXP3, is a nuclear transcription factor and as such is not suitable to purify viable cells by flow cytometry, and the CD25 membrane marker that is constitutively and highly expressed by most T reg cells is also transiently expressed by T eff cells. Initial clinical trials used magnetic bead sorting of T reg cells with the expectation that this process would enrich for cells expressing high levels of CD25, including T reg cells. The advent of clinical grade fluorescence-activated cell sorting allowed the addition of low expression of CD127 as an additional marker, which improved purification 137 . The first therapeutic evaluation of ex vivo-expanded polyclonal T reg cells was performed in haematopoietic stem cell transplantation (HSCT) and T1D using polyclonal T reg cells (FIG. 3) .
Preclinical data in mice demonstrated that T reg cells control alloimmune responses. Indeed, T reg cell depletion exacerbated graft-versus-host disease (GVHD) after allogeneic HSCT, and T reg cell repletion controls GVHD 138, 139 . This preclinical information provided the needed rationale to investigate T reg cell-based therapies to control GVHD in humans. A number of small-scale efforts that gauge toxicity and clinical efficacy have been reported, including the administration of autologous peripheral blood T reg cells expanded in vitro to patients with acute or chronic GVHD 140, 141 and the administration of partially human leukocyte antigen (HLA)-matched T reg cells from cord blood in conjunction with a classical GVHD prophylaxis regimen that consists of cyclosporine, sirolimus or mycophenolate mofetil 142 . In solid organ transplantation, the ONE study (performed by a consortium of institutions supported by the European Union) has investigated the safety and efficacy of T reg cells administered in a dose-escalating approach (from 0.5 million to 3.0 million cells per kg body weight) in order to examine both safety and potential efficacy 143 . It is estimated that, at the onset of T1D, approximately half of the β-cell mass remains functional and produces insulin but will be destroyed within a year. The administration of potent immunosuppressant drugs shortly after the onset of T1D can block the autoimmune process and prolong the 'honeymoon' period of the disease, but this occurs at the expense of severe side effects 144, 145 . This information strongly supports the exploitation of immune intervention at this time of the disease by boosting the T reg cell compartment. A first trial reported that
-T reg cells prolonged the honeymoon phase of patients with recently diagnosed T1D 146 , with clinical results lasting at least 1 year 147 . Another study sorted CD4 + CD25 high CD127 -T reg cells, labelled them with deuterated glucose and injected them into patients with recent-onset T1D. Labelled cells were detected at least 1 year later, and some of the patients maintained endogenous insulin production for 2 years after treatment 148 . These trials, which used large doses of polyclonal T reg cells in HSCT and T1D, have demonstrated that T reg cell injections are safe; that, despite extensive proliferation during ex vivo production, some of the cells can survive for long periods of time; and that there is evidence for potential therapeutic efficacy. In parallel, further clinical evaluation of ex vivo-expanded T reg cell therapies is warranted, which also calls for improvements in T reg cell purification and production.
The stability of these in vitro-generated T reg cells after they are infused into the patient is of obvious importance. The possibility of devising approaches to maintain the FOXP3 locus in a demethylated state is particularly enticing [149] [150] [151] . In one report, hydrogen sulfide maintained the expression of the methylcytosine dioxygenases TET1 and TET2, which catalyse conversion of 5-methylcytosine to 5-hydroxymethylcytosine in the Foxp3 gene, to establish a T reg cell-specific hypomethylation pattern and stable FOXP3 expression 152 . Drugs that imitate the action of hydrogen sulfide may prove of value to stabilize T reg cells and expand their function.
T reg cell-enhancing drugs
As discussed above, FOXP3 inhibits the PI3K-mTOR pathway 153 , and several studies in mice deficient in negative regulators of this pathway showed functional impairment of T reg cells and systemic autoimmunity 27, 68, 154 . Human T reg cells expand efficiently in the presence of the mTOR inhibitor rapamycin 155 . In SLE, activated mTOR in T cells accounts for several abnormalities, including the downregulation of the TCR companion signalling molecule CD3ζ, the expansion of T H 17 cell and double-negative T cell (express neither CD4 nor CD8) populations, which have been shown to contribute to tissue inflammation, and the contraction of T reg cell populations 60, 156, 157 . Administration of rapamycin has been reported to improve clinical outcomes in lupus-prone mice 158 and patients with SLE 159 (TABLE 2) . Moreover, rapamycin can block the production of antiphospholipid antibodies in lupus-prone mice 160 and improve renal allograft survival in patients with antiphospholipid syndrome 161 . Rapamycin is a promising drug for the treatment of patients with systemic autoimmunity and other inflammatory conditions because it normalizes numerous T cell functions, including those of T reg cells. A single-arm, open-label, phase I/II trial administered the mTOR inhibitor sirolimus (2 mg per day) to patients with active SLE who were unresponsive to, or intolerant of, conventional medications for 12 months Concurrent blockade of OX40L (also known as TNFSF4) and mTOR prevented graft rejection in a non-human primate GVHD model 163 . In a complementary approach, murine acute GVHD could be diminished with administration of FTY720, a sphingosine-1-phosphate (S1P) receptor antagonist 164 that promotes the activity of PP2A, thereby reducing mTOR activity 68 . It is noteworthy that FTY720 is currently being studied in clinical trials to prevent acute GVHD (including EudraCT 2004-000655-41). In a different approach, patients with acute GVHD who were treated with mTOR inhibitors together with a glycolipid (α-galactosylceramide (α-GalCer) in the form of RGI-2001) that promotes NK T cell function had an increased number of T reg cells and a reduced immune response 165 . In a negative feedback loop, FOXP3 expression is compromised when mTORC2 is activated, because mTORC2 prevents FOXO1 from entering the nucleus and stabilizing FOXP3 expression. Pyrazolopyrimidine derivative drugs, which promote the nuclear translocation of FOXO1 and simultaneously inhibit PI3K, are worthy of clinical investigation because they target both upstream and downstream components of mTORC2 signalling 166 .
Other molecules that limit mTOR activity work by diverse mechanisms of action but include S1P receptor blockers 167, 168 , antioxidants such as metformin and N-acetyl cysteine 169, 170 and calmodulin kinase type II and type IV inhibitors 111, 112 . It remains to be seen whether any of them will generate clinical traction.
Other modalities include targeting histone acetylation with inhibitors of specific histone deacetylases (such as HDAC6, which is expressed at higher levels in T reg cells than in conventional T cells). These inhibitors have been shown to selectively increase T reg cell function in lupus-prone mice and protect them from lupus nephritis 171, 172 . In addition, mice deficient in HDAC6 had T reg cells with improved suppressive activity, poor antibody responses to antigen 173 and curtailed autoimmune and inflammatory responses 174 .
Antigen-specific T reg cell therapies
The antigen specificity of T reg cells is poorly understood. TCR analysis indicates that the T reg cell repertoire is quite diverse; even the repertoire of activated eT reg cells 175 , which have probably developed in response to stimulation with self-antigens 46 , is diverse. It is, however, not known whether protection from autoimmunity is performed by T reg cells that recognize tissue-specific or ubiquitous self-antigens. The therapeutic efficacy of antigen-specific T reg cells should be higher than that of polyclonal T reg cells (reviewed previously 176 ). The advent of antigen-specific T eff cells that express a chimeric antigen receptor (CAR) and are used to treat patients with cancer 177 has instigated the consideration of developing antigen-specific T reg cell therapies (FIG. 3) .
Different sources of cells and different means to generate antigen specificity can be envisioned. Indeed, it is possible to turn T eff cells into T reg cells by overexpressing FOXP3. Likewise, the transduction of a TCR that recognizes an autoantigen, together with FOXP3, should generate antigen-specific artificial T reg cells. The best TCR constructs for efficient targeting and activation of T reg cells will have to be identified, as has been done for the CAR T eff cells 116 . Alternatively, purified antigen-specific T reg cells could also be used.
Proof-of-concept studies in animal models of disease using CAR T reg cells in which the CAR recognizes specific antigens have suggested the plausibility of this approach in clinical settings 178, 179 . However, the identification of an appropriate antigen in human autoimmune diseases is challenging, particularly for conditions in which more than one antigen is involved. This issue can be somewhat easily solved in the context of transplantation or immune responses to therapeutic proteins. HLA-A2 is a frequently mismatched alloantigen in transplantation. Human HLA-A2-specific CAR T reg cells were better than T reg cells expressing an irrelevant CAR at preventing xenogeneic GVHD caused by HLA-A2 + T cells in mice 179 . Furthermore, HLA-A2 CAR T cells were shown to alleviate alloimmune-mediated xenogeneic skin injury 180 .
Investigators have also considered the construction of T reg cells with a TCR that recognizes factor VIII in order to suppress the production of neutralizing antibodies in patients with haemophilia 181 ; these patients often develop immune responses to injected factor VIII. These proof-of-concept studies pave the way to clinical evaluation of CAR T reg cells in humans.
IL-2
High doses of IL-2 were initially used to promote T eff cell function against tumours, but this approach was undermined by side effects 182 . The realization that T reg cells have higher affinity receptors for IL-2 (owing to the expression of CD25) and therefore stronger IL-2R-mediated Proof of concept studies have been done in xenogeneic graft-versus-host disease (GVHD), xenogeneic skin transplantation and haemophilia. Dendritic cells (DCs) that express lymphocyte antigen 75 (LY75) and present self-antigen, or that become tolerogenic because of cytokine exposure, can induce antigen-specific T reg cells. The latter has been tried in patients with rheumatoid arthritis, in which the tolerogenic DCs were incubated with citrullinated peptides. Peptides and copolymers with amino acid sequences that are similar to those of self-antigens can induce T reg cells and ameliorate disease manifestations in patients with multiple sclerosis or systemic lupus erythematosus (SLE). Finally, the highly sensitive interleukin 2 receptor (IL-2R) on T reg cells makes low doses of IL-2 sufficient for preferential T reg cell expansion. This approach has been tested in hepatitis C virus-induced vasculitis, GVHD and SLE. The biological activity of IL-2 can be increased by forming immune complexes of IL-2 with anti-IL-2 monoclonal antibodies (mAbs), which selectively stimulate T reg cells. COP-I, copolymer-I; dsDNA, double-stranded DNA; FACS, fluorescence-activated cell sorting; FOXP3, forkhead box P3; HSP60, heat shock protein 60; IFNγ, interferon-γ; MHC, major histocompatibility complex; TCR, T cell receptor; T eff cell, effector T cell; TGFβ, transforming growth factor-β. ▶ signalling than T eff cells suggested that administration of IL-2 at a lower dose than used for T eff cells should promote T reg cell expansion and function 10 . The demonstrated safety profile of IL-2 and its capacity to specifically activate T reg cells at low doses 10 have delivered early clinical benefits.
Low-dose IL-2.
In addition to the expression of the high-affinity receptor, T reg cells are also intrinsically more sensitive to IL-2 than are T eff cells 57 , resulting in high levels of STAT5 phosphorylation and specific enhancement of the gene activation programme downstream of IL-2R signalling 183 . Also, IL-2 was shown to block the differentiation of naive CD4 + T cells into pro-inflammatory T H 17 cells 184 and to favourably influence the balance between T FH cells and follicular regulatory T cells 185 . Before T reg cells were discovered, delivery of IL-2 with a vaccinia virus containing the IL2 gene to MRL/lpr mice resulted in prolonged survival and shrinkage of the double-negative T cell population, particularly the population that produces IL-17 (REFS 186, 187 ). The dual nature of IL-2 signalling was uncovered in 1993, when mice deficient for IL-2 (REF.
188 ) (and later for IL-2R signalling 189, 190 ) were shown to develop lethal autoimmunity and inflammation rather than immunodeficiency. T reg cells were later found to be defective in these mice and responsible for the phenotype 191 . Simultaneously, investigators who had used IL-2 to treat patients with cancer noticed a major expansion of T reg cells 192 . At that time, IL-2 was an approved marketed drug for activating immune effector responses to treat cancer 193 , but it had numerous and severe side effects 10 . The Klatzmann group initiated the first proof-ofconcept evaluation of low-dose IL-2 for the treatment of autoimmune diseases in 2006. Patients with hepatitis C virus (HCV)-induced vasculitis were known to have decreased numbers of T reg cells, which was corrected after treatment with B cell depletors 194 or antivirals 195 in complete responders but not in nonresponders or partial responders. This suggested that T reg cell stimulation drives the clinical response. Daily doses of IL-2 that were about 30-fold lower than those used in patients with cancer were administered to patients with HCV-induced vasculitis and resulted in expansion of T reg cells, without affecting T eff cells, and in substantial clinical improvement 9 . In a parallel study, administration of low-dose IL-2 to patients who had developed GVHD and were resistant to steroids resulted in a preferential expansion of T reg cells and clinical improvement 196 . Indeed, very low doses of IL-2 have even been used to prevent the development of GVHD 197 . Low-dose IL-2 has been used in patients with alopecia areata, characterized by autoimmune-mediated hair loss, and showed impressive hair regrowth in a subset of patients 198 . Importantly, this study documented that the IL-2 administration expanded T reg cell populations not only in the blood but also at the hair follicles, the site of the autoimmune process.
Several reports have demonstrated clinical improvement and expansion of the T reg cell population in patients with SLE following administration of low-dose IL-2 (REFS [199] [200] [201] ). A caveat to this observed success is early evidence that the IL-2-IL-2R-STAT5 signalling pathway in T cells is compromised in many patients with SLE 81 , and, thus, administration of IL-2 to those patients is unlikely to improve the disease. However, because IL-2 has the potential to reverse several pathogenic processes involved in the development of SLE, including poor T reg cell function, increased IL-17 production, increased T FH cell activity and an expanded population of double-negative T cells 202 , controlled studies could reveal clinical usefulness.
As IL-2 can activate T eff cells or T reg cells in a dosedependent manner and its side effects are also dosedependent, defining the therapeutic window for safe and specific activation of T reg cells is crucial. On the basis of a dose-finding double-blind placebo-controlled study 203 , a dose of 1-2 million international units (MIU) per injection is used in an ongoing phase IIb trial in SLE and T1D. This dose allows for a 100-200% increase in T reg cell numbers after five injections.
Results of early clinical trials have confirmed the excellent safety profile of low-dose IL-2 and, other than local reactions at the injection sites, have shown no severe side effects. Low-dose IL-2 has been tried in a variety of autoimmune diseases and has had clinical benefit linked to increased numbers of T reg cells (D.K., unpublished observations). Ongoing registered clinical trials addressing the clinical efficacy of low-dose IL-2 are listed in Modified IL-2. In more inflammatory settings, such as in rheumatoid arthritis or during flares of various autoimmune diseases, it may be necessary to achieve more than a 200% increase in T reg cell numbers. Intense work has therefore been put into generating mutant IL-2 proteins that have increased specificity for T reg cells over T eff cells 204 . Another approach to improve the potential therapeutic utility of IL-2 is to increase its half-life. The halflife of IL-2 after subcutaneous injection is a few hours, although its effect on T reg cells is dose-dependent and lasts much longer. Current trials often use IL-2 in a series of three to five injections repeated over weeks or single weekly injections. Pegylation 205 carrier proteins such as immunoglobulin fragments 206 or albumin 207, 208 increases its half-life (FIG. 3) . However, these approaches risk rendering the recombinant fusion proteins immunogenic or even able to stimulate T eff cells. The trade-off between ease of use and risks now needs to be investigated.
Complexing IL-2 with antibodies that affect its binding to the trimeric or dimeric IL-2Rs has also been explored 209 . Some of these complexes preferentially expand T reg cell populations and improve disease in lupus-prone mice 187 . Although the initial development used murine antibodies, the identification of human antibodies or the humanization of murine antibodies that can confer increased specificity of IL-2 complexes for T reg cells would allow their use in the clinic. Human antibodies that favour the expansion of T eff cells over T reg cells have been described 210 , and recently, a fully human anti-IL-2 antibody, which stabilizes IL-2 in a conformation that results in the preferential STAT5 phosphorylation of T reg cells in vitro and selective expansion of T reg cells in vivo, has been developed 211 .
Dendritic cells
Lymphocyte antigen 75 (LY75; also known as DEC-205 and CD205) belongs to the lectin family of surface receptors that function as antigen uptake and processing receptors for tolerogenic DCs 212 . Thus, cognate antigen presentation by immature LY75 + DCs to naive CD4 + T cells can promote the development of functional T reg cells that have the canonical T reg cell signature (including expression of chemokine receptors, CTLA4 and IL-10) 44 . In these T reg cells, the CNS2 region of the FOXP3 promoter is hypomethylated and allows for stable expression of FOXP3 and prolonged cell survival 213 .
In the preclinical setting, LY75 + DCs promoted tolerance through the generation of T reg cells and protected mice from the development of T1D and experimental autoimmune encephalomyelitis (EAE), which result from pancreas-embedded 214 and myelin oligodendrocyte glycoprotein (MOG) 215 antigens, respectively. Tolerogenic DCs can be generated by exposing DCs to either IL-4 and retinoic acid or IL-10 and TGFβ. DCs from patients with rheumatoid arthritis cultured under such conditions led to the development of T reg cells and T H 2 cells in culture, both of which produced immunosuppressive cytokines 216 . This approach has been tried in patients with rheumatoid arthritis in a phase I clinical trial wherein the patients were treated with autologous tolerogenic DCs that were differentiated ex vivo from peripheral blood mononuclear cells in the presence of IL-4, granulocyte-macrophage colony-stimulating factor (GM-CSF) and an NF-κB inhibitor and treated with citrullinated peptides (Rheumavax). These tolerogenic DCs were then injected intradermally to 18 patients with rheumatoid arthritis who carried the shared HLA-DR epitope, which recognizes the citrullinated peptides. The treatment was safe and biologically active, and 1 month after the injection, the number of T eff cells decreased, the ratio of T reg cells to T eff cells increased, and serum levels of inflammatory cytokines and chemokines (IL-15, IL-29, CXCL1 and CXCL11) were reduced 217 .
Tolerogenic peptides
Myelin basic protein (MBP) is an antigen derived from myelin sheaths. A polypeptide known as copolymer-I (COP-I), which contains the four immunogenic amino acids found in MBP, was designed and proved clinically efficient in treating patients with multiple sclerosis 218 . In the murine model of EAE, administration of COP-I was associated with induction of T reg cells 219 .
A human anti-double-stranded DNA monoclonal antibody was the basis for the design of the hCDR1 peptide, which, when administered to mice and humans with lupus, resulted in clinical improvement and induction of FOXP3-expressing T cells 220, 221 that also expressed BCL-X L (REFS 222, 223 ). In a phase II clinical trial wherein patients with SLE were treated with four different doses of hCDR1, the peptide was safe and well tolerated with some promise of clinical benefit 224 . Both histone peptides derived from a histone autoepitope and the pConsensus peptide, which is based on T cell determinants in the variable chain heavy (V H ) region of a murine anti-DNA antibody, were beneficial in treating lupus-prone mice, and both approaches involved the induction of both CD8 + and CD4 + T reg cells 225, 226 . A peptide derived from heat shock protein 60 (HSP60), designated HSP60 p216 , was shown to be tolerogenic in a murine model for rheumatoid arthritis. HSP60 p216 -specific CD8 + T reg cells were induced following the administration of tetramers composed of HSP60 p216 and the murine MHC class Ib molecule Qa1. These cells used perforin and IL-15 to suppress pathogenic T FH cells and T H 17 cells, reduce the production of collagen-specific autoantibodies and inhibit the development of arthritis in these mice 227 .
A different approach to developing tolerogenic peptides for rheumatoid arthritis utilizes the citrullination of peptides, as anti-citrullinated peptide antibodies are a hallmark of this disease. Thus, a multi-epitope peptide was designed that contained sequences of citrullinated human autoantigens (such as type II collagen, vimentin, fibrinogen and filaggrin). This compound (Cit-ME) induced T reg cells and improved clinical indices in a rat adjuvant-induced arthritis model 228 . A general limitation of using tolerogenic peptides is the fact that the autoimmune response spreads to different epitopes, even those located on the same protein 229 , and, thus, the peptide may lose efficacy over time.
Limitations and considerations
Although therapies that promote T reg cells have great potential, there are some caveats to their prospective use. Information generated in mice may not be readily transferable to humans because human and murine T reg cells are not identical. For instance, some human T reg cell subsets are not suppressive, whereas murine T reg cells are functionally more homogeneous. Patients with established autoimmune disease already harbour high numbers of autoreactive T eff cells and memory T cells and have an inflammatory milieu that can be difficult for T reg cells to overcome. For instance, in patients with rheumatoid arthritis, the inflammatory cytokines (such as IL-6 and TNF) that are present in their synovial fluid make the T eff cells resistant to suppression by T reg cells 230 . Also, the T eff cells from patients with SLE are more resistant to suppression by T reg cells in vitro 79, 231 . Under such conditions, it would take a high number of autoantigen-specific T reg cells to suppress those pathogenic cells. Projecting from data from the mouse models, it would be wise first to get rid of the autoreactive T eff cells and only then administer T reg cells. Approaches to increase the sensitivity of T eff cells to the suppressive effects of T reg cells are also needed.
For cell therapies, T reg cells that are expanded ex vivo are not necessarily stable nor long-lived. Epigenetic changes to the expanded T reg cells could make them stable. In the setting of ex vivo T reg cell expansion and transfusion, it is still difficult to demonstrate T reg cell purity and potency. It is unlikely that all of the expanded cells will be T reg cells or that their suppressive function in vitro will necessarily be reproduced in vivo. As with any cell-based immunotherapy, treatment with T reg cells could induce an inflammatory reaction following the cell infusion (cytokine release syndrome).
For treatment with IL-2, determining the exact IL-2 'low dose' for human studies may prove difficult because the therapeutic window may vary according to the inflammatory context, and, in some patients, it may stimulate the T eff cells.
Therapies: cancer
As discussed above, T reg cells enter tumours, and except for in cancers that are driven by inflammation, T reg cells promote tumour growth and progression through multiple inhibitory pathways. Therefore, several approaches have been considered to deplete T reg cells, limit their entry into the tumour tissue and/or disrupt their function (TABLE 4) .
Nonspecific T reg cell targeting
Traditional chemotherapeutics, such as cyclophosphamide and others, have been shown to reduce the number and immunosuppressive function of T reg cells through various mechanisms 115 . Low-dose cyclophosphamide (known as metronomic chemotherapy) was reported to deplete T reg cells by inhibiting proliferation and inducing apoptosis and to decrease their function by reducing FOXP3 and GITR expression 232, 233, 234 . In addition, tyrosine kinase inhibitors (sunitinib, sorafenib and imatinib) have been shown to inhibit intratumoural T reg cell expansion and function 117, 235, 236 . However, although these approaches can limit T reg cell proliferation and function, they are not an ideal choice, as they are not specific to tumour-associated T reg cells.
Blocking T reg cell trafficking into tumours
Tumours have microenvironments rich in cytokines and chemokines that promote the accumulation of T reg cells, which express high levels of chemokine receptors 237, 238 . 
Complement-mediated cytotoxicity
A process that leads to the lysis of cells coated with immunoglobulin, a marker that is able to activate complement.
Blocking the interactions between chemokines and their receptors -such as that of CCL22 and CCR4, which constitutes the dominant intratumoural T reg cell recruitment mechanism in numerous tumours -reduces intra tumoural accumulation of T reg cells and suppresses tumour growth in mice 238, 239 . Similarly, intraperitoneal injection of an anti-CCR10 immunotoxin in mice with orthotopically implanted human ovarian carcinoma cells that showed hypoxia-induced overexpression of CCL28 (the ligand for CCR10) resulted in complete intra tumoural T reg cell depletion and reduced tumour growth 114 . Clinical studies conducted with a humanized anti-CCR4 antibody (mogamulizumab, KW-0761), which depletes CCR4 + T reg cells by antibody-dependent cell-mediated cytotoxicity (ADCC), showed intratumoural T reg cell depletion and antitumour activity with minimal to moderate toxicity 240, 47 . However, a recent update of two clinical phase I/II trials reported unclear long-term antitumour effects 241 . Occasional serious side effects were reported as well 240, 242 .
Comparative flow cytometric and RNA sequencing analysis of T reg cells and conventional T cells in tumour and normal tissues and in the circulation of patients with breast carcinoma showed that CCR4, in addition to being highly expressed in intratumoural T reg cells, is also expressed in T reg cells in the peripheral blood and in activated T eff cells, although in somewhat lesser amounts 123 . It is therefore possible that the CCR4-depleting antibody affects the survival of peripheral T reg cells, which leads to unwanted effects, and affects the survival of T eff cells as well, which limits antitumour responses. Indeed, both T reg cell and T eff cell numbers were decreased in patients who received anti-CCR4 antibody treatment in a clinical study 243 . These data highlight the need to identify molecules that are specific to tumour-dwelling T reg cells to use as therapeutic targets. Notably, two recent studies showed that intratumoural T reg cells from various human tumours express CCR8 at levels that are much higher than those in peripheral T reg cells, or conventional T cells in the periphery of tumours, indicating that CCR8 is a novel promisingly targetable molecule 123, 244 . CCR8 is the receptor for the CCL1 and CCL18 chemokines, both of which are differentially upregulated in intratumoural myeloid cells 123 .
T reg cell depletion
Numerous specific intratumoural T reg cell depletion strategies have been investigated and reviewed extensively 115, 117, 130 . Antibodies directed against CD25 (daclizumab, basiliximab and LMB-2 (REFS [245] [246] [247] [248] [249] ), a single-chain variable fragment (scFv) fused to exotoxin A of Pseudomonas spp.), have been used to kill T reg cells by ADCC and complement-mediated cytotoxicity. Also, a fusion protein containing IL-2 and diphtheria toxin protein (denileukin diftitox, Ontak) was designed to induce direct cytotoxicity. Preclinical and clinical studies using a combination of anti-CD25 antibodies and DC vaccines reported beneficial effects, but clinical studies with denileukin diftitox had mixed results 115, 117, 130, 250 . Notably, patients with metastatic melanoma treated with denileukin diftitox showed no clinical benefit and severe autoimmune side effects 251 . Depletion of T reg cells from HSCT to treat relapses of leukaemia in patients who did not develop GVHD during the first transplant produced better outcomes 252 . These data suggest that global T reg cell depletion has variable efficacy and the potential to induce systemic complications.
Immune checkpoint inhibitors
Immune checkpoint molecules are upregulated in T reg cells and thus could be targeted to modulate T reg cell function. A widely used approach to activate antitumour immunity is immune checkpoint blockade with antibodies against CTLA4 (ipilimumab and tremelimumab), which induce tumour regression and improve survival of patients with metastatic melanoma [253] [254] [255] . Although CTLA4 targeting was initially aimed to reactivate T eff cells, CTLA4 is also highly expressed on T reg cells, and CTLA4 targeting induces T reg cell depletion in the tumour microenvironment by ADCC 256 . Furthermore, CTLA4 antibody binding to T reg cells contributed, independently of its T eff cell binding, to the antitumour activity of this molecule, thus leading to a synergistic maximal anti tumour effect in a mouse melanoma model 257 . Intriguingly, however, conditional CTLA4 depletion in T reg cells increased the immunosuppressive functions of T reg cells in adult mice 258 , indicating that the role of CTLA4 in T reg cells needs to be further investigated. Undesirable autoimmune manifestations in a subset of patients treated with anti-CTLA4 antibodies indicated systemic loss of T reg cell activity 253, 259 . Anti-CTLA4 antibodies have complimentary activity with therapies targeting anti-PD-1 (nivolumab), another checkpoint inhibitor expressed by T reg cells, and their combined use is more beneficial than either agent alone 260 . Furthermore, because anti-CTLA4 and anti-PD-1 therapies benefit only a small subset of patients with cancer and may have undesirable effects, such as the development of autoimmune manifestations, other molecules that are expressed by T reg cells with superior immunosuppressive activity, such as T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT), LAG3 and T cell immunoglobulin mucin domain 3 (TIM3; also known as HAVCR2), are being considered and evaluated in early-phase clinical trials 261, 262 . TIM3 targeting may be more advantageous than CTLA4 and PD-1 targeting, because expression of TIM3 is restricted to intratumoural T cells, and hence its inhibition is less likely to interfere with T cell functions in other sites; TIM3-deficient mice do not exhibit autoimmune disorders 263 .
Engagement of TNFRs
GITR belongs to the group of TNFRs that provides co-stimulatory signalling to increase T cell activation and is induced in T cells upon activation, but GITR is also highly expressed (higher than in the periphery) in intratumoural T reg cells. Ligation of GITR with an agonistic antibody was shown to suppress T reg cell activity, reduce T reg cell numbers and decrease T reg cell lineage stability selectively in tumours and also limit tumour growth in mice [264] [265] [266] [267] , particularly when administered together with CTLA4 (REF.
268
) or PD-1 inhibitors 269 . GITR ligation, similar to CTLA4 blockade, also improves T eff cell functions and renders T eff cells resistant to inhibition by T reg cells 270 . Mice treated with an anti-GITR antibody showed dramatically reduced tumour growth and the intratumoural T reg cells in these mice had decreased expression of HELIOS (also known as IKZF2, a transcription factor that maintains T reg cell stability and function) and increased IFNγ production. These data provide a mechanistic explanation for the reduction of T reg cell lineage stability by GITR ligation and reinforce GITR as a therapeutic target to reverse the immunosuppressive function of intratumoural T reg cells. Although side effects have been reported with GITR ligation 271 , these may be avoided by using low doses of anti-GITR antibody, which are sufficient for T reg cell conversion in mice 272 . In addition, the anti-GITR antibody has been reported to increase the number of T reg cells in the periphery 273, 274 . Another TNF receptor family member, OX40, has similar pattern of expression and functional properties to GITR and, upon ligation, leads to impaired T reg cell function and improved T eff cell responses 275 . On the basis of the promising results from the animal studies, human GITR and OX40 agonists, as well as agonists for other members of the TNFR family (CD27 and 4-1BB) are currently being evaluated in clinical trials as monotherapies or in combination with other agents 266, [276] [277] [278] . Two newly developed antagonistic antibodies that target TNFR2, which is expressed by the most suppressive intratumoural T reg cells and by human cancers, disabled the ability of TNFR2 to bind TNF and activate NF-κB, killed T reg cells and also induced killing of tumour cells 279 . Interestingly, TNFR2 can exert bidirectional control on T reg cells because it can induce their proliferation and activation through the NF-κB, AP1 and MAPK pathways 280 . TNFR2 agonists have been used as a novel strategy to induce T reg cell expansion in vitro and to inhibit GVHD in vivo [281] [282] [283] . Therefore, TNFR2 is an exciting molecular target for the development of T reg cell-based immunomodulatory therapies to treat both cancer and autoimmune diseases using antagonistic or agonistic antibodies respectively.
IDO inhibitors
IDO, an enzyme with two isoforms (IDO1 and IDO2), converts tryptophan to kynurenine, resulting in depletion of tryptophan, a molecule that is central to T cell proliferation and differentiation. Lack of tryptophan and upregulation of kynurenine diminishes T cell proliferation and survival and induces the differentiation of T cells into T reg cells 128, 284, 285 . In the tumour microenvironment, IDO is produced by plasmacytoid DCs and by tumour cells in response to inflammatory stimuli, such as IFNγ, which leads to decreased T eff cell responses and increased T reg cell responses. IDO1 is more widely expressed than IDO2 and is overexpressed and activated in many human cancers, Preliminary studies have shown that the combination of IDO and PD-1 inhibitors is fairly safe although not entirely without side effects. Interestingly, it was reported that combined treatment of mice with melanoma with an IDO inhibitor and a tumour vaccine induced conversion of T reg cells into T H 17-like cells in the tumour-draining lymph node and increased T eff cell activation and antitumour efficacy, suggesting that the combined use of IDO inhibitors and tumour vaccines could be an alternative strategy to deactivate T reg cells by converting them to T eff -like cells 288 .
T reg cell-derived cytokines
In another approach, the effects of the anti-inflammatory cytokines (TGFβ, IL-10 and IL-35) that are secreted at high levels by T reg cells in the tumour microenvironment were blocked using neutralizing antibodies. Blockade of TGFβ expressed on the surface of T reg cells improved the anti-melanoma immune response 282 and suppressed metastasis of pancreatic tumours in mice 113, [289] [290] [291] . Anti-IL-35 limited tumour growth in multiple mouse models of human cancer 284 .
Novel intratumoural T reg cell targets NRP1, a receptor for the immune cell-expressed ligand SEMA4A, is selectively and highly expressed in intratumoural T reg cells and correlates with poor prognosis in patients with melanoma 292 . NRP1 regulates T reg cell function and survival in the inflammatory tumour environment through ligation with SEMA4A, and targeting this axis can inhibit intratumoural T reg cell function 67, 293 . NRP1-deficient intratumoural T reg cells lose their immuno suppressive function and produce IFNγ (a T eff cell cytokine) while retaining FOXP3 expression, thus exhibiting a phenotype that was named T reg cell fragility (REF.
293
Mice lacking NRP1 in T reg cells or treated with blocking antibodies to NRP1 or SEMA4A exhibit delayed tumour growth and have no autoimmune responses. Furthermore, IFNγ produced by NRP1-deficient intratumoural T reg cells drives the fragility of adjacent NRP1-expressing T reg cells, thereby amplifying the effect and leading to tumour regression; IFNγ receptor inactivation abrogates the anti-PD-1 tumour response, as shown in a fibrosarcoma mouse model 293 . These findings indicate that NRP1 is a potential therapeutic target, which could reverse the immuno suppressive function of intratumoural T reg cells and improve the efficacy of checkpoint blockade therapies while maintaining peripheral tolerance.
Another recent study found that the c-REL subunit of the canonical NF-κB pathway is required for the maintenance of the active status of T reg cells 294 . REL genetic ablation or degradation by pentoxifylline, a US Food and Drug Administration-approved drug, downregulates HELIOS and impairs the molecular identity and suppressive function of T reg cells, indicating that c-REL can be targeted to inhibit T reg cell function 294 . Pentoxifylline did not reduce growth of established tumours as a monotherapy but potentiated the effect of PD-1 blockade and was well tolerated in mice and patients.
Oxygen-sensing propyl hydroxylases promote tumour growth by inducing T reg cell function and limiting T eff cell function. Genetic or pharmacological inhibition of the oxygen-sensing propyl hydroxylases limits tumour metastasis to the lungs 295 . Because T reg cells in tumour tissues diversify to adapt to the tumour microenvironment, characterization of the immune features of the tumour-infiltrating cells has gained wide attention for both predicting clinical outcomes and deciding which immunotherapy may work the best 296, 297 . The immune landscape of each tumour should probably dictate the immune approach most expected to be of clinical value.
Conclusions and future directions
Immunotherapy has been well established in the treatment of autoimmune diseases and is expected to substantially advance the treatment of cancer. In autoimmune diseases, most of the established approaches address the over-reactive autoinflammatory response and have been successful in organ-specific diseases including rheumatoid arthritis, IBD, psoriasis and others. However, parallel approaches have been discouraging for systemic autoimmune diseases. Similarly, checkpoint inhibitors have made substantial contributions in the treatment of at least certain types of tumour.
Restoring or empowering the regulatory component of the immune system has gained substantial traction, as it may provide an alternative approach to the manipulation of the effector component and could even be used as a primary therapeutic approach for autoimmune and transplantation-related diseases, as well as cancer.
In most organ-specific and systemic autoimmune diseases, the numbers of T reg cells and their functional status are not universally decreased, suggesting that, although T reg cell malfunction is dominant and drives disease pathology in certain patients, it does not do so in others. Simply speaking, any trial attempting to empower T reg cells in all patients who present with an autoimmune disease may be subject to type 2 (false negative) errors, and a treatment that could be beneficial for a subset of patients could be erroneously rejected. A cohort of patients who have a deficit in T reg cell number should be identified and T reg cell-enhancing medications should be administered to only these patients. Similarly, elimination of T reg cells in patients with cancer may benefit only those in whom T reg cells outnumber T eff cells in the tumour.
Expansion of T reg cells ex vivo before reinfusion has been considered extensively in early clinical trials. This particular approach is confounded by a number of problems inherent to cell therapies or specifically to T reg cells. Cell therapy, outside a research setting or a specialized centre, presents myriad logistical and financial burdens that may preclude its applicability to common autoimmune diseases or patients receiving transplant organs. T reg cells may be expanded ex vivo, but their instability may be a serious limiting factor. After being expanded in vitro in high concentrations of IL-2, they will probably die after being infused into patients, where the concentrations of IL-2 are low. Methods to stabilize T reg cells -for example, by increasing the methylation status of the FOXP3 locus or increasing the effect of FOXP3 on its target genes (for example, by suppressing special AT-rich sequence-binding protein 1 (SATB1), a genome organizer that is expressed in T cells and regulates chromatin structure and gene expression 298 ) -should be explored.
Although it has not been documented in patients, one possible issue with T reg cell therapy is that the newly expanded T reg cells in the periphery easily convert to effector cells, and if the percentage of these cells is high, there may be a flare of the inflammatory process in the individual recipient.
The possibility of further engineering T reg cells (transfected with the FOXP3 gene) with TCRs that recognize known antigens or autoantigens and are fused to the intracellular domains of signalling proteins that are able to confer a regulatory phenotype is tantalizing. This approach could be of great value in patients with haemophilia or receiving transplant organs. It could be equally valuable to patients with organ-specific autoimmune diseases in whom one or a few culprit autoantigens are known to be involved, but this approach would be more cumbersome in patients with systemic autoimmune diseases. Again, this approach should be limited to patients in whom a T reg cell numerical deficiency drives autoimmune pathology.
Expansion or empowerment of T reg cells in vivo is more realistic and, if successful, could benefit many patients whose care is not linked to major centres. Low-dose IL-2 has been claimed to be helpful in uncontrolled studies, and ongoing controlled studies should determine the clinical usefulness of this drug. There are a number of issues that may surface with administering low-dose IL-2 to patients with autoimmune diseases. First, the short half-life of IL-2 (the drug itself or its biological effect), which may be even shorter in patients with autoimmune diseases, could be problematic. Next, the therapeutic window between low-dose and high-dose IL-2 is very narrow, and this may cause side effects in some patients. Last, but equally important, is the possibility that IL-2 does not elicit a signalling response in T reg cells from patients with autoimmune diseases as it does in healthy individuals. The problem of the short half-life of IL-2 has been recognized, and a number of fusion molecules have been developed. The poor IL-2-elicited signalling response has been largely ignored, but approaches that involve co-engagement of other surface molecules (for example, SLAMF3 (also known as LY9)) may offer ways to restore the defective generation of phosphorylated STAT5. In this article, we have discussed molecules, such as mTOR, that limit T reg cell function and can be targeted with adjuvant drugs to IL-2 to increase the function of T reg cells. PP2A activity enhancers (such as ceramide) may increase PP2A activity, which is needed for the proper function of T reg cells.
The challenges to suppressing T reg cells in tumours loom larger than those to expand their function. Obviously, we need to better understand the nature and development of T reg cells in tumours. Some of the obvious big questions are what molecules enable T reg cells to enter tumours, do tumour cells or the tumour microenvironment further propagate T reg cell stability and function, and do T reg cells develop from naive CD4 + T cells after they are inside the tumour. Current technologies involving singlecell RNA sequencing of tumour cells and infiltrating inflammatory cells are expected to provide these muchneeded insights. Systemic inhibition of T reg cells likely carries the risks of not depleting T reg cells in the tumour and of unleashing an autoinflammatory response similar to those already reported in patients receiving checkpoint inhibitors. Biologics directed against chemokines and/or their receptors that enable T reg cell entry into the tumour should gain traction. Alternatively, approaches to deliver T reg cell-disabling or T reg cell-depleting biologics to the tumour in a specific manner could be therapeutically important.
An exciting new concept comes from data that detail the role of T reg cells present in organs targeted by the inflammatory response and their unexpected ability to repair damaged tissues
. Although purely speculative at this point, it is exciting to consider delivering engineered T reg cells to the kidneys of patients with lupus nephritis or to the pancreas of patients with T1D.
Although expanding and empowering T reg cells to treat autoimmune disease are actively being explored, suppressing them in cancer is still in the nascent stage. The expected reward if T reg cells can be manipulated is high given the currently used side-effect-laden indiscriminate immunosuppressant drugs in the treatment of autoimmune diseases and the toxic drugs used in patients with cancer.
Box 2 | T reg cells in wound repair and tissue regeneration
Lymphocytes, including CD4 + and CD8 + T cells, are recruited to sites of inflammation and promote tissue injury. Regulatory T (T reg ) cells also accumulate in sites of inflammation, such as the skeletal muscle after injury, where they promote the switch from an inflammatory to a regenerative state and persist for at least 1 month 308 . These T reg cells express high levels of amphiregulin (AREG), an epithelial growth factor (EGF) family protein, which promotes muscle regeneration by activating the EGF receptor (EGFR) signalling axis 308 . T reg cells that express AREG can also protect lungs from infection-induced damage 309 . AREG controls the immune response by regulating T reg cell function 310 . Involvement of AREG-EGFR signals in T reg cell-mediated tissue regeneration is also observed in skin injury and promotes wound healing 311, 312 . Furthermore, skin T reg cells preferentially reside close to hair follicle stem cells (HFSCs) and help HFSC-mediated hair regeneration 313 . Paracrine effects of T reg cells were also shown to promote cardiomyocyte proliferation during pregnancy and after myocardial infarction 314 . T helper 1 (T H 1) cells and T H 17 cells have been shown to promote neuroinflammation, but remyelination is compromised in the absence of lymphocytes 315 , indicating that some lymphocytes are pro-regenerative in the brain. Indeed, T reg cells directly promote remyelination independently of immunomodulation, and when T reg cells are deleted, the process is impaired 316 . The ability of T reg cells to contribute to tissue repair expands their importance far beyond controlling the immune response and suggests that these cells can be used to reverse advanced tissue damage caused by immune or non-immune processes.
